+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for Treating Hyperuricemia Market - Global Forecast 2026-2032- Product Image
Drugs for Treating Hyperuricemia Market - Global Forecast 2026-2032- Product Image
Sale

Drugs for Treating Hyperuricemia Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6078774
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drugs for Treating Hyperuricemia Market is projected to reach USD 3.17 Billion in 2026. It is expected to continue growing at a CAGR of 7.28%, reaching USD 4.81 Billion by 2032.

Hyperuricemia Treatment: Executive Overview

Drugs for treating hyperuricemia address elevated serum urate associated with gout, recurrent flares, urate deposition, and related comorbidities. The therapeutic landscape includes urate-lowering approaches, medicines used during acute flares, and supportive strategies shaped by renal function, cardiovascular risk, drug interactions, adherence, and the severity of disease. Clinical decision-making increasingly emphasizes sustained urate control, individualized treatment selection, and long-term monitoring rather than episodic symptom relief alone.

How Hyperuricemia Care Is Becoming More Individualized

The treatment landscape is shifting from reactive management toward treat-to-target care, with clinicians using serial serum urate measurements and flare history to guide escalation. Greater attention to chronic kidney disease, cardiovascular conditions, metabolic disorders, and medication-related hyperuricemia is influencing prescribing and monitoring practices. Oral therapy remains central, while specialist-supervised and infusion-based options have a role for patients with severe disease or inadequate response to conventional treatment. Patient education, adherence support, dietary counseling, and shared decision-making are increasingly important because treatment benefits depend on sustained use.

Artificial Intelligence Strengthens Diagnosis, Risk Stratification, and Monitoring

Artificial intelligence can support hyperuricemia care by identifying patients at risk of gout from longitudinal clinical records, laboratory results, imaging, and medication histories. Predictive models may help clinicians recognize likely treatment nonadherence, estimate flare risk, prioritize follow-up, and detect patients who require closer renal or cardiovascular monitoring. AI-enabled decision support could also assist with dose-adjustment prompts and drug-interaction screening. However, reliable implementation requires representative training data, transparent validation, privacy safeguards, clinician oversight, and prospective evidence that improves outcomes without reinforcing disparities.

Regional Insights: Different Access and Care Priorities

North America generally emphasizes guideline-based treat-to-target management, specialty care, and digital monitoring, while affordability and adherence remain practical concerns. Europe reflects variation among national reimbursement systems, clinical pathways, and diagnostic access, with the European emphasis on coordinated chronic-disease management. Asia-Pacific combines substantial urban healthcare capacity with uneven access across countries and rural areas, alongside dietary, genetic, and comorbidity considerations. Latin America faces differences in diagnosis, medicine availability, and continuity of care between public and private systems. The Middle East is shaped by metabolic comorbidities, specialist concentration, and healthcare modernization. Africa has substantial opportunities to improve diagnostic recognition, laboratory access, medicine availability, and continuity of chronic treatment.

Group Insights: Policy, Trade, and Health-System Context

ASEAN markets differ in regulatory maturity, reimbursement, and urban-rural access, making adaptable treatment pathways important. BRICS countries span large and diverse populations with varied laboratory capacity, domestic manufacturing capabilities, and public-health priorities. The European Union benefits from shared regulatory structures but retains national differences in reimbursement and care delivery. G7 systems commonly have stronger specialist and laboratory infrastructure, while still addressing aging populations, multimorbidity, and treatment adherence. GCC countries often combine comparatively well-resourced healthcare systems with high burdens of metabolic risk factors and a growing focus on preventive care. NATO members represent diverse health systems, but continuity of care, procurement resilience, and management of chronic disease remain common priorities.

Country Insights: Diverse Clinical and Access Environments

Australia and Canada place emphasis on primary-care management, specialist access, and equitable service delivery across geographically dispersed communities. Brazil and Mexico face regional disparities in diagnosis, reimbursement, and continuity of treatment. China and India combine expanding urban healthcare capacity with large populations requiring scalable screening, laboratory, and adherence programs. Japan has an aging population and established chronic-disease infrastructure, with careful attention to polypharmacy and renal function. South Korea is supported by advanced digital health capabilities and structured clinical services. France, Germany, Italy, and Spain operate within mature European healthcare environments while differing in reimbursement, prescribing pathways, and regional organization. The United Kingdom emphasizes guideline-led care and primary-care follow-up. The United States offers broad therapeutic and specialist capabilities, but access, affordability, insurance coverage, and continuity can vary substantially. Russia’s care environment is influenced by regional health-system variation, procurement conditions, and access to specialist monitoring.

Priorities for Leaders: Improve Persistence, Access, and Evidence

Industry leaders should design therapies and services around sustained urate control, clear dosing instructions, manageable monitoring requirements, and clinically meaningful patient outcomes. Evidence generation should include people with renal impairment, cardiovascular comorbidities, polypharmacy, and diverse demographic backgrounds. Partnerships with clinicians and health systems can strengthen diagnostic pathways, laboratory follow-up, patient education, and adherence support. Digital tools should complement-not replace-clinical judgment and should be evaluated for safety, usability, and equity. Regional access strategies should reflect reimbursement rules, procurement realities, local treatment guidelines, and the capabilities of primary-care networks.

Research Methodology: Evidence-Based Market Assessment

This executive summary is based on the defined scope of drugs used to treat hyperuricemia and on a structured review of clinical, therapeutic, regulatory, health-system, and geographic considerations. The assessment organizes findings across six required regions, six multinational groups, and fifteen countries, while separating established care patterns from emerging opportunities. It excludes market estimates, market sizing, market shares, forecasts, and unsupported company-specific claims. Interpretations should be validated against current clinical guidelines, regulatory communications, peer-reviewed evidence, reimbursement policies, and local epidemiological data before being used for investment or operational decisions.

Conclusion: Build Patient-Centered, Measurable Hyperuricemia Care

Hyperuricemia treatment is evolving toward earlier recognition, individualized urate-lowering strategies, and continuous monitoring of clinical response and safety. The greatest opportunities lie in improving persistence, integrating care for renal and cardiometabolic comorbidities, expanding reliable laboratory access, and adapting delivery models to local health-system conditions. Artificial intelligence may enhance risk identification and follow-up when deployed responsibly, but clinical evidence and human oversight remain essential. Leaders that align therapeutic innovation with affordability, adherence, equitable access, and measurable patient outcomes will be best positioned to address the varied needs of global hyperuricemia care.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drugs for Treating Hyperuricemia Market, by Drug Class
7.1. Introduction
7.2. Recombinant Uricase
7.3. Uricosuric Agents
7.3.1. Lesinurad
7.3.2. Probenecid
7.4. Xanthine Oxidase Inhibitors
7.4.1. Allopurinol
7.4.2. Febuxostat
8. Drugs for Treating Hyperuricemia Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Drugs for Treating Hyperuricemia Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Drugs for Treating Hyperuricemia Market, by Prescription Type
10.1. Introduction
10.2. Branded
10.3. Generic
11. Drugs for Treating Hyperuricemia Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Drugs for Treating Hyperuricemia Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Drugs for Treating Hyperuricemia Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Alembic Pharmaceuticals Limited
15.2. AstraZeneca PLC
15.3. Cipla Limited
15.4. Dr. Reddy's Laboratories Ltd.
15.5. Glenmark Pharmaceuticals Ltd.
15.6. Hikma Pharmaceuticals PLC
15.7. Ipsen Pharma
15.8. Jiangsu Hengrui Medicine Co., Ltd.
15.9. Julphar
15.10. Lupin Limited
15.11. Macleods Pharmaceuticals Ltd.
15.12. Mylan N.V.
15.13. Novartis AG
15.14. Pfizer Inc.
15.15. Sun Pharmaceutical Industries Ltd.
15.16. Takeda Pharmaceutical Company Limited
15.17. Teijin Pharma Limited
15.18. Torrent Pharmaceuticals Ltd.
15.19. Zydus Lifesciences Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Drugs for Treating Hyperuricemia Market, Years Considered for the Study
FIGURE 2. Global Drugs for Treating Hyperuricemia Market, Research Design
FIGURE 3. Global Drugs for Treating Hyperuricemia Market, Research Framework
FIGURE 4. Global Drugs for Treating Hyperuricemia Market, Data Triangulation
FIGURE 5. Global Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2025 vs 2032 (%)
FIGURE 13. Global Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Drugs for Treating Hyperuricemia Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Drugs for Treating Hyperuricemia Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Drugs for Treating Hyperuricemia Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Drugs for Treating Hyperuricemia Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Drugs for Treating Hyperuricemia Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Drugs for Treating Hyperuricemia Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Drugs for Treating Hyperuricemia Market Segmentation & Coverage
TABLE 2. Global Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 3. Global Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Recombinant Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Recombinant Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Recombinant Uricase Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Uricosuric Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Uricosuric Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Uricosuric Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lesinurad Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lesinurad Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lesinurad Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Probenecid Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Probenecid Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Probenecid Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Xanthine Oxidase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Xanthine Oxidase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Xanthine Oxidase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Allopurinol Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Allopurinol Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Allopurinol Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Febuxostat Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Febuxostat Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Febuxostat Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 26. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 33. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 43. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Drugs for Treating Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Drugs for Treating Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 57. North America Drugs for Treating Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. North America Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 59. North America Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 60. North America Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 61. North America Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 62. North America Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 63. North America Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 64. Latin America Drugs for Treating Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Latin America Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 66. Latin America Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 67. Latin America Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 68. Latin America Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 69. Latin America Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. Latin America Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 71. Europe Drugs for Treating Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Europe Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 73. Europe Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 74. Europe Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 75. Europe Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 76. Europe Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Europe Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 78. Middle East Drugs for Treating Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Middle East Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 80. Middle East Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 81. Middle East Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 82. Middle East Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 83. Middle East Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Middle East Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 85. Africa Drugs for Treating Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Africa Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 87. Africa Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 88. Africa Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 89. Africa Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 90. Africa Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. Africa Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 92. Global Drugs for Treating Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. ASEAN Drugs for Treating Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. ASEAN Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 95. ASEAN Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 96. ASEAN Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 97. ASEAN Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 98. ASEAN Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. ASEAN Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 100. GCC Drugs for Treating Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. GCC Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 102. GCC Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 103. GCC Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 104. GCC Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 105. GCC Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. GCC Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 107. European Union Drugs for Treating Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. European Union Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 109. European Union Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 110. European Union Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 111. European Union Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 112. European Union Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. European Union Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 114. BRICS Drugs for Treating Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. BRICS Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 116. BRICS Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 117. BRICS Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 118. BRICS Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 119. BRICS Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. BRICS Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 121. G7 Drugs for Treating Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. G7 Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 123. G7 Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 124. G7 Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 125. G7 Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. G7 Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. G7 Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 128. NATO Drugs for Treating Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. NATO Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 130. NATO Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 131. NATO Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 132. NATO Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 133. NATO Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. NATO Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 135. Global Drugs for Treating Hyperuricemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. United States Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 137. United States Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 138. United States Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 139. United States Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 140. United States Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 141. United States Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. United States Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 143. Canada Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 144. Canada Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 145. Canada Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 146. Canada Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 147. Canada Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 148. Canada Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. Canada Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 150. Mexico Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 151. Mexico Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 152. Mexico Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 153. Mexico Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 154. Mexico Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 155. Mexico Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. Mexico Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 157. Brazil Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 158. Brazil Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 159. Brazil Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 160. Brazil Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 161. Brazil Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 162. Brazil Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. Brazil Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 164. United Kingdom Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 165. United Kingdom Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 166. United Kingdom Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 167. United Kingdom Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 168. United Kingdom Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 169. United Kingdom Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. United Kingdom Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 171. Germany Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 172. Germany Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 173. Germany Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 174. Germany Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 175. Germany Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 176. Germany Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Germany Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 178. France Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 179. France Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 180. France Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 181. France Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 182. France Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. France Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. France Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 185. Russia Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 186. Russia Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 187. Russia Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 188. Russia Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 189. Russia Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 190. Russia Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. Russia Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 192. Italy Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 193. Italy Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 194. Italy Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 195. Italy Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 196. Italy Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 197. Italy Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. Italy Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 199. Spain Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 200. Spain Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 201. Spain Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 202. Spain Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 203. Spain Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 204. Spain Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Spain Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 206. China Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 207. China Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 208. China Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 209. China Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 210. China Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 211. China Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. China Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 213. India Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 214. India Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 215. India Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 216. India Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 217. India Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 218. India Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 219. India Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 220. Japan Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 221. Japan Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 222. Japan Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 223. Japan Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 224. Japan Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 225. Japan Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Japan Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 227. Australia Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 228. Australia Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 229. Australia Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 230. Australia Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 231. Australia Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 232. Australia Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. Australia Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 234. South Korea Drugs for Treating Hyperuricemia Market Size, 2017-2032 (USD Million)
TABLE 235. South Korea Drugs for Treating Hyperuricemia Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 236. South Korea Drugs for Treating Hyperuricemia Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 237. South Korea Drugs for Treating Hyperuricemia Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 238. South Korea Drugs for Treating Hyperuricemia Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 239. South Korea Drugs for Treating Hyperuricemia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. South Korea Drugs for Treating Hyperuricemia Market Size, by Prescription Type, 2017-2032 (USD Million)
TABLE 241. Global Drugs for Treating Hyperuricemia Market Share, by Key Player, 2025
TABLE 242. Global Drugs for Treating Hyperuricemia Market, Key Experts

Companies Mentioned

  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Ipsen Pharma
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Julphar
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Market - Global Forecast 2026-2032 - Product Image

Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 185 Pages
  • Global
From
Hyperuricemia Drugs Market Report 2026 - Product Image

Hyperuricemia Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Hyperuricemia - Pipeline Insight, 2026 - Product Image

Hyperuricemia - Pipeline Insight, 2026

  • Clinical Trials
  • 180 Pages
  • Global
From
Hyperuricemia Drug Pipeline Analysis Report 2026 - Product Image

Hyperuricemia Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.